MedPath

Octafluoropropane

Generic Name
Octafluoropropane
Brand Names
Definity, Luminity, Optison
Drug Type
Small Molecule
Chemical Formula
C3F8
CAS Number
76-19-7
Unique Ingredient Identifier
CK0N3WH0SR
Background

Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients.

Indication

Used as an ultrasound contrast imaging in cardiology and radiology.

FDA Expands Optison Ultrasound Enhancing Agent Approval for Pediatric Cardiac Imaging

• The FDA has expanded approval for GE HealthCare's Optison, allowing the ultrasound enhancing agent to be used in pediatric patients with suboptimal echocardiograms, following successful Phase IV clinical trials. • Optison, which uses gas-filled microbubbles to improve visualization of heart chambers and endocardial borders, has been safely used in over 5 million adult patients since its original FDA approval in 1997. • The expanded indication represents a significant advancement in pediatric cardiac imaging, potentially improving diagnostic accuracy and quality of care for children requiring echocardiographic assessment.
© Copyright 2025. All Rights Reserved by MedPath